AIDS 2010 18th International AIDS Conference (IAC) July 18-23 2010 Vienna, Austria

Conference Reports for NATAP


AIDS 2010 18th International AIDS Conference (IAC) July 18-23 2010 Vienna, Austria

	Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP - (07/23/10) HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10) IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina (08/16/10) Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10) Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV - (08/29/10) IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina (08/16/10) A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results - (08/15/10) Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy - (08/15/10) Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks - (08/15/10) SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment - (08/10/10) The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients - (08/10/10) Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses - (08/10/10) The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients - (08/10/10) Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks - (08/10/10) A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results - (08/10/10) HBV related complications in HIV positive patients during HAART therapy - LAM resistance and high serum HBV-DNA & advancd liver disease - (08/10/10) Vienna Declaration: 'decriminalize illicit drug use as an HIV prevention measure' - (08/10/10) Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10) High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10) Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF - (08/04/10) Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (08/04/10) Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) - (08/04/10) Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study - (08/04/10) The impact of switching to etravirine on efavirenz-related CNS toxicity - (08/04/10) Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 - (08/04/10) Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population - (08/04/10) Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program - (08/04/10) Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: "34% Reduction in Mortality in Early Arm" - (08/04/10) Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data - (08/04/10) Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 - written by Mark Mascolini - (07/29/10) HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10) Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada - written by Mark Mascolini - (07/27/10) Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir - written by Mark Mascolini - (07/27/10) Tenofivir Once-Daily PrEP in MSM Friday Late Breaker - (07/27/10) The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline - (07/27/10) Abacavir vs Tenofovir - Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration - (07/27/10) Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms - written by Mark Mascolini - (07/27/10) Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen - written by Mark Mascolini - (07/26/10) Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir - written by Mark Mascolini - (07/26/10) HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women's Study - (07/26/10) Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic - (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) - (07/26/10) Infection With Resistant Virus More Than Doubles Risk of Virologic Failure - (07/26/10) HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10) 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10) Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10) Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine - (07/23/10) HIV Raises Heart Disease Risk 60% in People Over 49 - (07/23/10) HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on 'When To Start' - (07/23/10) Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10) Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System - (07/23/10) Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study - (07/23/10) Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era - (07/23/10) Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10) HPV Vaccine Prevents HPV Lesions and Infection in Men - written by Mark Mascolini - (07/22/10) Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER - written by Mark Mascolini - (07/22/10) Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10) Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis - (07/22/10) The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects - (07/22/10) VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation - BI press release - (07/22/10) Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients - (07/22/10) TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures - written by Mark Mascolini - (07/22/10) Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) - (07/22/10) S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive - written by Mark Mascolini - (07/22/10) Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER - written by Mark Mascolini - (07/22/10) Two to Three Times Higher Hodgkin Risk in First Months of ART - written by Mark Mascolini - (07/22/10) Five Times Higher Risk of Intracranial Hemorrhage With HIV - written by Mark Mascolini - (07/22/10) Types of Kidney Problems May Be Changing as HAART Era Matures - written by Mark Mascolini - (07/22/10) Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 - (07/22/10) Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients - (07/22/10) METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks - (07/22/10) Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study - (07/22/10) New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients - written by Mark Mascolini - (07/21/10) Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis - written by Mark Mascolini - (07/21/10) CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV - written by Mark Mascolini - (07/21/10) Cancer Rates in HIV+ in Atlanta: 'Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV' - written by Mark Mascolini - (07/21/10) A Year of ART Does Not Ease Anal Cancer Harbingers in Men - written by Mark Mascolini - (07/21/10) Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival - written by Mark Mascolini - (07/21/10) HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study - written by Mark Mascolini - (07/21/10) Congresswoman Barbara Lee Calls for $6 Billion for Global Fund - (07/21/10) S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates - (07/21/10) Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs - (07/21/10) HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study - (07/21/10) 'Start HIV Therapy Earlier, IAS-USA Panel Recommends' - (07/20/10) Bill Clinton on HIV/AIDS: Much More Needs to be Done - (07/20/10) Bill Clinton, Gates: Fight AIDS more efficiently - (07/20/10) Tenofovir AIDS gel protects women in study - (07/20/10) Tenofovir Gel found to reduce AIDS risk in women - (07/20/10) New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10) New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10) Number Globally of HIV-positive in treatment rose by a quarter last year - (07/20/10) Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum - written by Mark Mascolini - (07/19/10) Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study - written by Mark Mascolini - (07/19/10) Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative - written by Mark Mascolini - (07/19/10) Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups - written by Mark Mascolini - (07/19/10) Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort - written by Mark Mascolini - (07/19/10) HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/19/10) Once- Versus Twice-Daily Raltegravir When Switching From a PI - written by Mark Mascolini - (07/19/10) Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial - written by Mark Mascolini - (07/19/10) Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL - written by Mark Mascolini - (07/19/10) Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint - Abbott Press Release - (07/19/10) Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid - (07/19/10) TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation - (07/19/10) Tenofovir Gel Reduced HIV Transmission - pdf of Science Mag publication attached - (07/19/10) First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive - written by Mark Mascolini - (07/19/10) Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10) Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10) Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 - written by Mark Mascolini - (07/19/10) New IAS-USA Guidelines Urge Earlier Therapy for HIV Patients - (07/19/10) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study - (07/19/10) AIDS group fears annual HIV costs may hit $35 bln - (07/19/10) HIV/AIDS numbers from around the world - (07/19/10) CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate - (07/19/10) Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV - (07/19/10) 18th Int'l AIDS Conference opens in Vienna - (07/19/10) World AIDS Conference (IAC) Opens - to hear progress on drugs, money worries - (07/19/10)